Savant Capital’s West Pharmaceutical WST Stock Holding History

Savant Capital’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$560K	Buy	1,780 +910	+105%	+$278K	﹤0.01%	1158
2026 Q1	$218K	Buy	+870	New	+$216K	﹤0.01%	1359
2025 Q1	–	Sell	-1,003	Closed	-$329K	–	1447
2024 Q4	$329K	Buy	1,003 +131	+15%	+$41.2K	﹤0.01%	1063
2024 Q3	$262K	Buy	872 +75	+9%	+$23K	﹤0.01%	1154
2024 Q2	$263K	Buy	797 +99	+14%	+$35K	﹤0.01%	1032
2024 Q1	$276K	Sell	698 -92	-12%	-$34K	﹤0.01%	925
2023 Q4	$278K	Sell	790 -100	-11%	-$35.4K	﹤0.01%	725
2023 Q3	$334K	Buy	890 +56	+7%	+$21.7K	0.01%	624
2023 Q2	$319K	Buy	834 +167	+25%	+$59.7K	0.01%	634
2023 Q1	$231K	Buy	+667	New	+$195K	﹤0.01%	650
2022 Q3	–	Sell	-810	Closed	-$245K	–	582
2022 Q2	$245K	Buy	+810	New	+$264K	0.01%	476

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Savant Capital's WST Position: Q2 2026 in Review

Savant Capital increased its West Pharmaceutical (WST) stake by 105% in Q2 2026, buying an estimated $278K and bringing the position to 1,780 shares worth $560K. The position accounts for ﹤0.01% of the portfolio, ranked #1158.

Savant Capital first reported a position in WST in Q2 2022 and has held it in 11 quarters since. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

Savant Capital held 1,780 shares of West Pharmaceutical worth $560K as of Q2 2026.
Savant Capital bought 910 West Pharmaceutical shares in Q2 2026, an estimated $278K.
West Pharmaceutical made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1158 holding.
Savant Capital first reported a position in West Pharmaceutical in Q2 2022 and has held it in 11 quarters since.
831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.